MARKET

IPHA

IPHA

INNATE PHARMA SA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.40
-0.26
-3.39%
Closed 16:00 02/24 EST
OPEN
7.28
PREV CLOSE
7.66
HIGH
7.40
LOW
7.28
VOLUME
23.27K
TURNOVER
--
52 WEEK HIGH
8.24
52 WEEK LOW
5.61
MARKET CAP
552.86M
P/E (TTM)
12.75
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of IPHA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IPHA stock price target is 12.00 with a high estimate of 17.50 and a low estimate of 8.50.

EPS

IPHA News

More
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA
  • GlobeNewswire · 02/14 21:41
  • IPHA LOSS NOTICE: ROSEN LAW FIRM, NATIONAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Innate Pharma S.A.; Encourages Investors with Losses in Excess of $100K to Contact the Firm IPHA
  • GlobeNewswire · 02/11 00:31
  • SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA
  • ACCESSWIRE · 02/10 22:35
  • SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Innate Pharma S.A. and Encourages Investors with Losses to Contact the Firm
  • ACCESSWIRE · 02/04 00:00

Industry

Biotechnology & Medical Research
-2.96%
Pharmaceuticals & Medical Research
-2.86%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About IPHA

Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.
More

Webull offers kinds of Innate Pharma SA stock information, including NASDAQ:IPHA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPHA stock news, and many more online research tools to help you make informed decisions.